

Cancelled before Active Statement

Statement on Discontinuation of the Study	
Sponsor	ABCSCG (Austrian Breast & Colorectal Cancer Study Group)
EudraCT No.	2009-009874-28
Study Code	ABCSCG 34; GA6182E1
Study Title	Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancer
Phase	III
Study Period	NA
No. of Sites	NA
No. of Subjects	0
Publications	NA
<p>Statement on discontinuation of the study: Sponsor rejected study before study start due to results of 2 Ph-III studies with sunitinib in advanced breast cancer which did not meet their primary endpoints. No subjects were recruited, therefore no results/data are available.</p>	